Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

医疗免责声明

本网站所含信息无意推荐自我管理健康问题、医疗条件或健康。本网站无意认可或推荐任何特定类型的医疗、医生或治疗机构。如果读者有任何与医疗保健相关的问题，请及时致电或咨询您的医生或医疗保健提供者。本网站所含信息不应被任何读者用于忽视医疗和/或健康相关建议，或作为推迟向医生或合格医疗保健提供者咨询的依据。抗击结直肠癌组织不对本网站提供的信息承担任何责任。

地点

MS status

Recruitment Status

阶段

药物

允许先接受免疫治疗

NCT ID

Title key word search

添加审判日期

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	阶段	Date Added	地点	Prior IO Allowed	CRC-directed	Status	药物	标签
NCT ID NCT06634875	TitleIsunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS)	阶段第二阶段	Date Added 2024-10-10	地点 California, United States	Prior IO Allowed 是	CRC-directed 是	Status 招聘	药物	标签 MSS/ MMRp
NCT ID NCT06589440	TitlePhase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)	阶段第二阶段	Date Added 2024-09-19	地点 New Jersey, United States Texas, United States Washington, United States	Prior IO Allowed 没有	CRC-directed 是	Status 招聘	药物 Balstilimab, Botensilimab	标签 MSS/ MMRp
NCT ID NCT06566755	TitleCadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer	阶段第三阶段	Date Added 2024-08-22	地点中国	Prior IO Allowed 没有	CRC-directed 是	Status 招聘	药物	标签 MSS/ MMRp
NCT ID NCT06558773	TitleGSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.	阶段第二阶段	Date Added 2024-08-19	地点中国	Prior IO Allowed 是	CRC-directed 是	Status 尚未招聘	药物	标签 MSS/ MMRp
NCT ID NCT06515314	TitleHRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors	阶段第 1 阶段	Date Added 2024-07-23	地点中国	Prior IO Allowed 是	CRC-directed 没有	Status 招聘	药物	标签 MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06514651	TitleMAQ-001 in Patients With Advanced Solid Tumors	阶段第 1 阶段	Date Added 2024-07-23	地点法国	Prior IO Allowed 是	CRC-directed 没有	Status 招聘	药物	标签 MSI-H/ MMRd
NCT ID NCT06513221	TitleA Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab	阶段	Date Added 2024-07-22	地点	Prior IO Allowed 没有	CRC-directed 是	Status	药物	标签 MSS/ MMRp
NCT ID NCT06508307	TitleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors	阶段第 1 阶段	Date Added 2024-07-18	地点中国	Prior IO Allowed 是	CRC-directed 没有	Status 招聘	药物	标签 MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06493760	TitleA Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients	阶段第二阶段	Date Added 2024-07-10	地点中国	Prior IO Allowed 没有	CRC-directed 是	Status 招聘	药物	标签 MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06456515	TitleRegorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC	阶段不适用	Date Added 2024-06-13	地点中国	Prior IO Allowed 是	CRC-directed 是	Status 招聘	药物	标签 MSS/ MMRp

Showing 11 to 20 of 299 entries